Literature DB >> 18757341

Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer.

Salvatore Artale, Andrea Sartore-Bianchi, Silvio Marco Veronese, Valentina Gambi, Carolina Silvia Sarnataro, Marcello Gambacorta, Calogero Lauricella, Salvatore Siena.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18757341     DOI： 10.1200/JCO.2008.18.7286

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  79 in total

Review 1.  Colorectal cancer molecular biology moves into clinical practice.

Authors:  Colin C Pritchard; William M Grady
Journal:  Gut       Date:  2010-10-04       Impact factor: 23.059

2.  Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia.

Authors:  Fortunato Ciardiello; Sabine Tejpar; Nicola Normanno; Domenica Mercadante; Tracey Teague; Bruno Wohlschlegel; Eric Van Cutsem
Journal:  Target Oncol       Date:  2011-06-01       Impact factor: 4.493

3.  Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer.

Authors:  Alenka Ličar; Petra Cerkovnik; Srdjan Novaković
Journal:  Med Oncol       Date:  2010-07-20       Impact factor: 3.064

4.  The clinical, research, and social value of autopsy after any cancer death: a perspective from the Children's Oncology Group Soft Tissue Sarcoma Committee.

Authors:  Sheri L Spunt; Sara O Vargas; Cheryl M Coffin; Stephen X Skapek; David M Parham; Joan Darling; Douglas S Hawkins; Charles Keller
Journal:  Cancer       Date:  2011-10-17       Impact factor: 6.860

5.  Systemic steroid treatment can desensitize the skin reaction due to regorafenib in a recurrence colorectal cancer patient.

Authors:  Keita Tashiro; Eiji Shinto; Yoshiki Kajiwara; Satsuki Mochizuki; Koichi Okamoto; Aya Nishizawa; Takahiro Satoh; Yoji Kishi; Hideki Ueno
Journal:  Int Cancer Conf J       Date:  2019-05-24

Review 6.  Molecular alterations and biomarkers in colorectal cancer.

Authors:  William M Grady; Colin C Pritchard
Journal:  Toxicol Pathol       Date:  2013-10-31       Impact factor: 1.902

7.  Tumour heterogeneity in the clinic.

Authors:  Philippe L Bedard; Aaron R Hansen; Mark J Ratain; Lillian L Siu
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

8.  Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications.

Authors:  Xingxiang Pu; Zhizhong Pan; Ying Huang; Ying Tian; Hongqiang Guo; Lin Wu; Xuexing He; Xinggui Chen; Shaodan Zhang; Tongyu Lin
Journal:  Oncol Lett       Date:  2012-10-10       Impact factor: 2.967

Review 9.  [Pathological diagnosis for individualized therapy of colorectal cancer].

Authors:  T Kirchner; A Jung
Journal:  Pathologe       Date:  2010-02       Impact factor: 1.011

Review 10.  Management of resectable colorectal lung metastases.

Authors:  Sing Yu Moorcraft; George Ladas; Anne Bowcock; Ian Chau
Journal:  Clin Exp Metastasis       Date:  2015-12-10       Impact factor: 5.150
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.